['atopic dermatitis']
['baricitinib', 'placebo', 'triamcinolone (optional)']

        Inclusion Criteria:

          -  Have moderate-to-severe Atopic Dermatitis (AD), as determined by all of the following:

               1. EASI of 12 or more

               2. Greater than or equal to 10% of body surface area involvement

               3. Diagnosed with AD at least 2 years prior

          -  Have a history of inadequate clinical response to other eczema treatments

        Exclusion Criteria:

          -  Females who are pregnant or nursing

          -  Participants who do not agree to use adequate contraception

          -  Are currently experiencing or have a history of:

               -  Skin conditions such as psoriasis or lupus erythematosus

               -  Skin disease that requires frequent hospitalizations or intravenous treatment

               -  Compromised immunity

          -  Serious illness that could interfere with study participation, or a clinically
             important deviation in physical examination, vital sign measurements,
             electrocardiograms, or abnormalities on laboratory tests

          -  Currently experiencing or have a history of:

               -  Active or latent Tuberculosis or specific immunity disorders and infections

               -  Malignancy or lymphoproliferative diseases in the last 5 years (or cervical,
                  basal or squamous skin cancer re-occurrence in the last 3 years)

               -  Human Immunodeficiency Virus (HIV)

               -  Hepatitis B, Hepatitis C, or chronic liver disease

          -  Have received certain types of vaccinations
      